Compare JPMorgan Chase & Co (JPM) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs Twist Bioscience Corp — how do they compare? JPMorgan Chase & Co trades at $342.5 (market cap $900.78B), while Twist Bioscience Corp trades at $93.93 (market cap $5.45B). The key difference: JPMorgan Chase & Co is far larger — about 165.3× Twist Bioscience Corp's market cap, and JPMorgan Chase & Co pays a 1.77% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| JPM | TWST | |
|---|---|---|
Market Cap | $900.78B | $5.45B |
Volume | 10,479,943 | — |
Sector | Financials | Health |
52-Week High | $346.91 | $102.88 |
52-Week Low | $282.84 | $24.16 |
Dividend Yield | 1.77% | — |
Enterprise Value | — | $5.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase trades at $339.90, down 0.35% on the day, with strong technical momentum showing bullish moving averages and key support at $339. The company reported mixed Q4 2025 earnings but beat expectations in Q1 and Q2 2026, with revenue growing to $181.85 billion in 2025. Analyst consensus remains positive with a $372.73 price target, though CEO Jamie Dimon's recent warnings highlight economic risks.
JPMorgan presents a compelling investment case with solid fundamentals and Wall Street support, though investors face risks from macroeconomic volatility, cybersecurity threats, and geopolitical tensions. The stock's current valuation below analyst targets suggests potential upside if earnings momentum continues through upcoming quarterly results.
Twist Bioscience (TWST) trades at $87.41, down 6.86% today, with a bullish technical outlook despite recent earnings misses. The company shows strong revenue growth from $204M in 2022 to $377M in 2025, though it remains unprofitable with a -19.85% net margin. Analyst consensus is strongly bullish with 11 buy ratings and a $91.63 price target, while recent news highlights AI-driven drug discovery collaborations and upcoming Q3 earnings.
The stock presents growth potential through expanding synthetic biology applications and AI partnerships, but carries significant risk from persistent losses, negative cash flow, and high valuation multiples (P/S 13.94). Investors should weigh the company's innovation trajectory against its path to profitability amid competitive biotech pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
